Large employers have also reported substantial cost increases tied to GLP-1 coverage, prompting many to re-evaluate their benefit design
The GLP-1 receptor agonists segment dominated the market with a share of 86% in 2025, as GLP-1 receptor agonists are driving historic market expansion by transforming obesity and diabetes management into a billion-dollar global industry
Men exploring recovery goals can review how this fits into mens recovery and performance support under physician guidance
Neves LF, Duan J, Voelker A, Khanal A, McNally L, Steinbach-Rankins J, et al
Found Health's 2026 program details reflect increasing consumer demand for transparency in telehealth weight loss programs, particularly around insurance coverage, medication pathways, and total program cost